Perrigo Company plc (PRGO) - 2024 Annual Report Summary
Business Context and Reporting Period
This summary covers the Form 10-K for the fiscal year ended December 31, 2024. Perrigo is a leading pure-play self-care company operating primarily in North America and Europe. The company is organized into two reporting segments: Consumer Self-Care Americas (CSCA) and Consumer Self-Care International (CSCI). In 2024, Perrigo completed its transformation into a pure-play self-care company by divesting its Rare Diseases Business and Hospital & Specialty Business. The company is executing a "Three-S" strategy: Stabilizing store brands and infant formula, Streamlining the global portfolio, and Strengthening high-growth brands.
Key Financial Metrics
| Metric | 2024 | 2023 |
|---|---|---|
| Net Sales | $4,373.4 million | $4,655.6 million |
| Gross Profit | $1,542.7 million | $1,680.4 million |
| Gross Margin | 35.3% | 36.1% |
| Operating Income | $112.9 million | $151.9 million |
| Operating Margin | 2.6% | 3.3% |
| Net Loss | $(171.8) million | $(12.7) million |
| Diluted EPS | $(1.25) | $(0.09) |
| Operating Cash Flow | $362.9 million | $405.5 million |
| Total Debt Outstanding | $3.6 billion | $4.1 billion |
| Cash and Equivalents | $558.8 million | $751.3 million |
Material Changes vs. Prior Period
- Revenue Decline: Net sales decreased 6.1% to $4.37 billion. This was driven by a $206 million decrease in volumes (due to a later start to the cough/cold season and lower infant formula volumes), $50.6 million from divestitures, and $10.4 million from unfavorable foreign currency translation.
- Profitability Pressure: Operating income fell 25.7% to $112.9 million. Gross profit declined $137.7 million due to lower sales volumes and $17.5 million in infant formula remediation costs. These were partially offset by $56.6 million in savings from the Supply Chain Reinvention and Project Energize.
- Restructuring and Impairments: The company recorded $110.1 million in restructuring charges (primarily Project Energize) and $88.9 million in impairment charges (including $38.6 million for the Prevacid brand and impairments related to divested businesses).
- Divestitures: Completed the sale of the Rare Diseases Business for $244.5 million and the Hospital & Specialty Business for $13.3 million, realizing pre-tax gains of $5.8 million and $0.6 million, respectively.
- Debt Refinancing: Issued $1.065 billion in new senior notes (2032 Notes) to prepay Term Loan B and redeem $700 million of 2026 Notes, reducing total indebtedness by approximately $455 million year-over-year.
Guidance, Outlook, and Risks
Management Commentary: Management highlighted the successful stabilization of infant formula operations following FDA-mandated remediation, with production returning to reliable levels. The company is focused on executing "Project Energize," a global efficiency program expected to deliver $140-$170 million in annualized pre-tax savings by 2026. The launch of Opill (OTC birth control) in 2024 drove significant growth in the Women's Health category.
Key Risks and Contingencies:
- Legal Litigation: Significant exposure remains from price-fixing lawsuits related to the former Rx business and securities litigation. The company settled a major securities class action for $97 million and recorded additional provisions for opt-out cases. A $98 million insurance recovery was recognized in 2024.
- Regulatory: Ongoing FDA scrutiny of infant formula manufacturing requires continued investment in quality protocols. The company faces potential risks from the reclassification of codeine products in Ireland and other jurisdictions.
- Geopolitical: Conflicts in Ukraine and the Middle East pose supply chain risks, particularly for Active Pharmaceutical Ingredients (API) sourced from Israel.
- Goodwill Impairment: The company noted that goodwill fair value is sensitive to discount rates and market capitalization. A 75 basis point increase in the discount rate could trigger impairment for the CSCI reporting unit.
Investor Verification Checklist
- Infant Formula Recovery: Verify that production volumes and customer service levels for infant formula have fully normalized and that remediation costs are stabilizing as projected.
- Restructuring Execution: Monitor the realization of cost savings from "Project Energize" and the Supply Chain Reinvention Program against the $140-$170 million and $200-$300 million targets, respectively.
- Legal Reserves: Review the adequacy of the $76.8 million litigation accrual, particularly regarding the remaining opt-out securities cases and price-fixing MDL bellwether trials scheduled for 2025.
- Debt Covenants: Confirm continued compliance with the maximum first lien secured net leverage ratio (3.00:1.00) and interest coverage ratio (3.00:1.00) given the recent operating income decline.
- Opill Performance: Assess the long-term sales trajectory and market penetration of Opill to ensure it sustains the growth seen in the Women's Health category.